My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories, Inc. Class A Common Stock (NY:BIO)

297.95 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023
 
Via Benzinga
Bio-Rad to Present Company Overview at Jefferies Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Death Cross Looms Over Bio-Rad Laboratories Investors
 
Via Benzinga
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Recap: Bio-Rad Laboratories Q1 Earnings
 
Via Benzinga
Golden Cross Appears Before Bio-Rad Laboratories Investors
 
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Earnings Outlook For Bio-Rad Laboratories
 
Via Benzinga
Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Stocks Roar Back To Life; Still Pacing For Weekly Loss
Rebounding bank stocks, stellar Apple earnings, and a blowout jobs report are all helping stocks move significantly higher Friday afternoon. 
Via Talk Markets
Bio-Rad Reports First-Quarter 2023 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
From Bio-Rad Laboratories, Inc.
Via Business Wire
Why Atlassian Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
The 3 Most Promising Biotech Stocks to Buy Now
With the NIH requesting its biggest budget yet, these are the three most promising healthcare stocks to buy now. 
Via InvestorPlace
I Asked ChatGPT for 10 EV Stocks to Buy. Here’s What It Recommended.
What are the best EV stocks to buy? ChatGPT has different answers, depending on how it is asked. Here's what investors need to know. 
Via InvestorPlace
Bio-Rad to Participate in Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
New Agreement Enhances High-Parameter Panels on Cytek Cell Analysis Systems 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover
Danaher is reportedly looking to add to its wheelhouse to compete with Thermo. 
Via Investor's Business Daily
Thoughts For Thursday: All Eyes On The CPI
All eyes are on the release of the December Consumer Price Index data later today. 2023 has started as a relatively up year for equities and a continued downward trajectory seems necessary to keep the... 
Via Talk Markets
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio Rad Has Almost 40% Upside On Revenue Acceleration And Margin Improvement, Analyst Says
 
Via Benzinga
Bio-Rad To Participate in Fireside Chat During Credit Suisse’s 31st Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Third-Quarter 2022 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022
From Bio-Rad Laboratories, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  During Friday, 125 stocks hit new 52-week lows. 
Via Benzinga
Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely
One analyst doubts any deal could come to fruition. If it did, it would make sense. 
Via Investor's Business Daily
Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11
Reuters US-China Chip War: KLA Relaxes Chip Supply To China 
Via Benzinga
Bio-Rad Laboratories, Qiagen Mull Merger Of Equals
Bio-Rad Laboratories Inc (NYSE: BIO) is reportedly in talks to merge with Qiagen NV (NYSE: QGEN), but any agreement isn't likely for another few weeks or more, or it may not happen at all. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.